Fractyl Health, Inc. is a biotechnology company focused on developing innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company aims to transform the treatment landscape through its proprietary approach, which combines advanced medical technologies with a deep understanding of metabolic health. By addressing underlying issues related to metabolism, Fractyl seeks to improve patient outcomes and enhance overall health. Through its research and development efforts, the company is dedicated to delivering scalable and effective solutions that can significantly impact the lives of individuals struggling with these chronic conditions. Read More
The DJS Law Group announces that it is investigating claims on behalf of investors of Fractyl Health, Inc. (“Fractyl Health” or “the Company”) (NASDAQ: GUTS) for violations of the securities laws.
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability
BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Ms. Smith Weber will oversee finance, accounting, and investor relations; and will serve as a key strategic partner to the Company’s executive leadership team and Board of Directors.
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in a fireside chat at the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL.
Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November 12, 2025, at 4:30 p.m. ET.
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy
A new class of Maga Stocks is heating up, blending health, wellness, tech, and critical minerals into some of the most compelling stories on Wall Street today. Here’s why investors are watching:
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
